Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial2014 · 1,497 citations
2. 2Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma2008 · 78 citations
3. 3Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation1998 · 5,458 citations
4. 4<i>Batf3</i> Deficiency Reveals a Critical Role for CD8α ⁺ Dendritic Cells in Cytotoxic T Cell Immunity2008 · 2,034 citations
5. 5Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development1999 · 154 citations